Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer

Frontiers in Bioscience

Volumn 14, Issue 8, 2009, Pages 2904-2910

  Ji, Zhenyu ^a   Mei, Fang C ^a   Lory, Pedro L ^a   Gilbertson, Scott R ^a   Chen, Yijun ^b   Cheng, Xiaodong ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b Pharmaceutical University   (China)

Author keywords

Cancer inhibitor; Chemical genetic screening; High through put screening; HTS; Pancreatic cancer; Pancreatic ductal adenocarcinoma; RAS; Synthetic lethal screening; Transformation

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CELL LINE; CELL TRANSFORMATION; DRUG SCREENING; GENETICS; HUMAN; ONCOGENE RAS; PANCREAS TUMOR;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, RAS; HUMANS; PANCREATIC NEOPLASMS;

EID: 63849212056     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2735/3421     Document Type: Article

References (31)

1. A.J. Aguirre, N. Bardeesy, M. Sinha, L. Lopez, D.A. Tuveson, J. Horner, M.S. Redston, R.A. DePinho, Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17, 3112-3126 (2003). (Pubitemid 38040774)
2. P. Bevan, H. Ryder, I. Shaw, Identifying small-molecule lead compounds: the screening approach to drug discovery. Trends Biotechnol. 13, 115-121 (1995).
3. T.L. Blundell, Structure-based drug design. Nature 384, 23-26 (1996). (Pubitemid 26374536)
4. C. Caldas, S.A. Hahn, R.H. Hruban, M.S. Redston, C.J. Yeo, S.E. Kern, Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 54, 3568-3573 (1994). (Pubitemid 24225985)
5. R. Capdeville, E. Buchdunger, J. Zimmermann, A. Matter, Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat.Rev.Drug Discov. 1, 493-502 (2002).
6. S. Dolma, S.L. Lessnick, W.C. Hahn, B.R. Stockwell, Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer cell 3, 285-296 (2003). (Pubitemid 37443883)
7. B.J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, S. Fanning, J. Zimmermann, N.B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat.Med. 2, 561-566 (1996).
8. S.L. Forsburg, The art and design of genetic screens: yeast. Nat.Rev.Genet. 2, 659-668 (2001). (Pubitemid 33674788)
9. S.H. Friend, A. Oliff, Emerging uses for genomic information in drug discovery. N.Engl.J.Med. 338, 125-126 (1998). (Pubitemid 28042279)
10. W.C. Hahn, C.M. Counter, A.S. Lundberg, R.L. Beijersbergen, M.W. Brooks, R.A. Weinberg, Creation of human tumour cells with defined genetic elements. Nature 400, 464-468 (1999). (Pubitemid 29361801)
11. L.H. Hartwell, P. Szankasi, C.J. Roberts, A.W. Murray, S.H. Friend, Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064-1068 (1997). (Pubitemid 27517876)
12. S.R. Hingorani, E.F. Petricoin, A. Maitra, V. Rajapakse, C. King, M.A. Jacobetz, S. Ross, T.P. Conrads, T.D. Veenstra, B.A. Hitt, Y. Kawaguchi, D. Johann, L.A. Liotta, H.C. Crawford, M.E. Putt, T. Jacks, C.V. Wright, R.H. Hruban, A.M. Lowy, D.A. Tuveson, Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer cell 4, 437-450 (2003). (Pubitemid 38050041)
13. S.R. Hingorani, L. Wang, A.S. Multani, C. Combs, T.B. Deramaudt, R.H. Hruban, A.K. Rustgi, S. Chang, D.A. Tuveson, Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer cell 7, 469-483 (2005). (Pubitemid 40719130)
14. R.H. Hruban, M. Goggins, J. Parsons, S.E. Kern, Progression model for pancreatic cancer. Clin.Cancer Res. 6, 2969-2972 (2000). (Pubitemid 30637716)
15. L.H. Hurley, DNA and its associated processes as targets for cancer therapy. Nat.Rev.Cancer 2, 188-200 (2002). (Pubitemid 37328788)
16. E.M. Jaffee, R.H. Hruban, M. Canto, S.E. Kern, Focus on pancreas cancer. Cancer cell 2, 25-28 (2002). (Pubitemid 41043985)
17. A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, A. Ghafoor, E.J. Feuer, M.J. Thun, Cancer statistics, 2005. CA Cancer J.Clin. 55, 10-30 (2005). (Pubitemid 40310185)
18. Z. Ji, F.C. Mei, J. Xie, X. Cheng, Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J.Biol.Chem. 282, 14048-14055 (2007). (Pubitemid 47100411)
19. W.G. Kaelin Jr., The concept of synthetic lethality in the context of anticancer therapy. Nat.Rev.Cancer 5, 689- 698 (2005). (Pubitemid 41486362)
20. T.R. Kau, F. Schroeder, S. Ramaswamy, C.L. Wojciechowski, J.J. Zhao, T.M. Roberts, J. Clardy, W.R. Sellers, P.A. Silver, A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer cell 4, 463-476 (2003). (Pubitemid 38050043)
21. D.S. Klimstra, D.S. Longnecker, K-ras mutations in pancreatic ductal proliferative lesions. Am.J.Pathol. 145, 1547-1550 (1994). (Pubitemid 24378508)
22. M. Knockaert, N. Gray, E. Damiens, Y.T. Chang, P. Grellier, K. Grant, D. Fergusson, J. Mottram, M. Soete, J.F. Dubremetz, K. Le Roch, C. Doerig, P. Schultz, L. Meijer, Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem.Biol. 7, 411-422 (2000). (Pubitemid 30400044)
23. J. Lamb, E.D. Crawford, D. Peck, J.W. Modell, I.C. Blat, M.J. Wrobel, J. Lerner, J.P. Brunet, A. Subramanian, K.N. Ross, M. Reich, H. Hieronymus, G. Wei, S.A. Armstrong, S.J. Haggarty, P.A. Clemons, R. Wei, S.A. Carr, E.S. Lander, T.R. Golub, The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006). (Pubitemid 44497995)
24. J. Luttges, B. Schlehe, M.A. Menke, I. Vogel, D. Henne-Bruns, G. Kloppel, The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer 85, 1703-1710 (1999). (Pubitemid 29169670)
25. C.A. Moskaluk, R.H. Hruban, S.E. Kern, p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 57, 2140-2143 (1997). (Pubitemid 27247028)
26. M.M. Nociari, A. Shalev, P. Benias, C. Russo, A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J.Immunol.Methods 213, (1998) 157-167. (Pubitemid 28332808)
27. M. Tada, M. Ohashi, Y. Shiratori, T. Okudaira, Y. Komatsu, T. Kawabe, H. Yoshida, R. Machinami, K. Kishi, M. Omata, Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 110 227-231 (1996). (Pubitemid 26021622)
28. H. Wang, H. Han, D.D. Von Hoff, Identification of an Agent Selectively Targeting DPC4 (Deleted in Pancreatic Cancer Locus 4)-Deficient Pancreatic Cancer Cells. Cancer Res. 66, 9722-9730 (2006). (Pubitemid 44623673)
29. P. Workman, Towards intelligent anticancer drug screening in the post-genome era? Anticancer Drug Des 12, 525-531 (1997). (Pubitemid 27462417)
30. N. Yagoda, M. von Rechenberg, E. Zaganjor, A.J. Bauer, W.S. Yang, D.J. Fridman, A.J. Wolpaw, I. Smukste, J.M. Peltier, J.J. Boniface, R. Smith, S.L. Lessnick, S. Sahasrabudhe, B.R. Stockwell, RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447, 864-868 (2007). (Pubitemid 46920135)
31. J.H. Zhang, T.D. Chung, K.R. Oldenburg, A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J.Biomol.Screen. 4, 67-73 (1999). (Pubitemid 29278954)